Most patients with the most common form of childhood brain cancer saw their tumors shrink by half. Now the company, which hopes to ask regulators next year to approve the drug, is eyeing a big fundraise as a result.
Most patients with the most common form of childhood brain cancer saw their tumors shrink by half. Now the company, which hopes to ask regulators next year to approve the drug, is eyeing a big fundraise as a result.
